Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trialSanjay Ramakrishnan, Mona Bafadhel, Dan V. Nicolau et al.|The Lancet Respiratory Medicine|2021Cited by 434
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trialLy‐Mee Yu, Mona Bafadhel, Jienchi Dorward et al.|The Lancet|2021Cited by 310
Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxideSimon Couillard, Ian Pavord, Timothy Hinks et al.|Thorax|2021Cited by 169
Survival analysis of patients on maintenance hemodialysisA Chandrashekar, DRangarajan Rangarajan, Sanjay Ramakrishnan|Indian Journal of Nephrology|2014Cited by 100
Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trialSanjay Ramakrishnan, Mona Bafadhel, Richard Russell et al.|The Lancet Respiratory Medicine|2024Cited by 98